The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation

U.S. Government Information on Organ and Tissue Donation and Transplantation
About Us Terms and Topics FAQs Site Map   
External Web Site Policy
Organdonor.gov Go to U.S. Department of Health and Human Services Website organdonor.gov: Give the Gift of Life
 
Home  >  Legislation

Advisory Committee on Organ Transplantation

U.S. Department of Health and Human Services

Recommendations 53 & 54

The Advisory Committee on Organ Transplantation (ACOT) met on August 23-24, 2011, in Washington, DC, and unanimously agreed on the following two recommendations:

Recommendation 53: The ACOT recommends that the Secretary redefine Vascularized Composite Allografts (VCA) as “organs” under the National Organ Transplant ACT.

Recommendation 54:  The ACOT recommends to the Secretary that the FDA recognize and accept laboratory-developed testing performed in CLIA-certified, high-complexity histocompatibility laboratories.

Background
The ACOT concludes that the FDA’s investigational-use-only (IUO) and research-use-only (RUO) guidance document for laboratory-developed testing has serious unintended consequences for the field of transplantation, including:

  • Reduced access to transplantation for sensitized candidates
  • Reduced deceased donor availability for non-renal candidates without “virtual crossmatches”
  • No desensitization or post-transplant monitoring except on research protocols
  • The inability to provide high-resolution matching for HSCT transplantation
 


Logo Health Resources and Service Administration (HRSA)

 

 

 

 

 

 
Share This Page  External Web Site Policy  Facebook  YouTube
  • Mail
  • Delicious
  • Facebook
  • Digg
  • StumbleUpon
  • Twitter